The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene

Richard H. Duerr, Kent D. Taylor, Steven R. Brant et al. · Science · 2006 · 3K citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

David H. Miller, Omar Khan, William Sheremata et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

Bette K. Kleinschmidt‐DeMasters, Kenneth L. Tyler · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Life Sciences, Neurology, Neuroscience +12